The primary objective of the Immune Analysis Core is to establish standardized assays of cellular and humoral immune responses for the immunotherapeutic approaches being developed and tested in Individual Research Projects 1, 2 and 3 of the RPCI Ovarian Cancer SPORE. It will be also be responsible for enumerating and characterizing myeloid derived suppressor cells (MDSCs) by flow cytometry for Research Projects 4. The Core will routinely provide Ovarian Cancer SPORE investigators with high quality, state-of-the- art flow cytometry, cellular monitoring by ELISPOT, proliferation and cytotoxicity assays, and multiplex cytokine bead array.
The specific aims of the Immune Analysis Core are to: 1) Provide cell banking services for immune monitoring assays requiring viable mononuclear cells. 2) Provide state-of-the-art, multi-color, fluorescence activated cell sorting and analytical support for Individual Research Projects, Career Development and Developmental Research Projects. This includes high-speed sorting and multi-color analysis of cellular subsets. 3) Provide state-of-the-art ELISPOT, ELISA, proliferation and cytotoxicity assays for the functional characterization of antigen-specific T cell responses. 4) Provide state-of-the-art patient sample handling and assessment of immune responses, with standardized SOPs, quality assurance, quality control and data management practices to monitor assay performance and validate data quality. In addition to these established immunoassays services, the Immune Analysis Core will be instrumental in developing new methodologies and making them available to the SPORE investigators. It also has a significant educational role, working with all SPORE investigators including PI's, technicians and young investigators on their assay development, proper use of instrumentation and interpretation of their data.
Centralization and standardization of the performance of the immunoassays will facilitate head-to-head comparisons of the immunological therapies being tested using the same outcome measures and provide for more efficient use of the SPORE's resources.
|Szender, J Brian; Eng, Kevin H; Matsuzaki, Junko et al. (2016) HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecol Oncol 142:158-62|
|Kohrt, Holbrook E; Tumeh, Paul C; Benson, Don et al. (2016) Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer 4:15|
|Chen, Yichao; Xia, Rui; Huang, Yixian et al. (2016) An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun 7:13443|
|Wong, Jeffrey L; Obermajer, NataÅ¡a; Odunsi, Kunle et al. (2016) Synergistic COX2 Induction by IFNÎ³ and TNFÎ± Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunol Res 4:303-11|
|Shi, Liangrong; Chen, Lujun; Wu, Changping et al. (2016) PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res 22:1173-84|
|Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56|
|Winham, Stacey J; Pirie, Ailith; Chen, Yian Ann et al. (2016) Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 25:446-54|
|PrÃ¦stegaard, Camilla; Kjaer, Susanne K; Nielsen, Thor S S et al. (2016) The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiol 41:71-9|
|Earp, Madalene; Winham, Stacey J; Larson, Nicholas et al. (2016) A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget 7:7381-9|
|Zhao, Wenyuan; Chen, Beibei; Guo, Xin et al. (2016) A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources. Oncotarget 7:19060-71|
Showing the most recent 10 out of 73 publications